Roche’s lung cancer drug combo study shows improvement in progression-free survival
The study demonstrated that the Tecentriq combination has more effectively reduced the disease progression in patients compared to those who received Avastin plus chemotherapy. IMpower150 is a multicenter,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.